These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36101508)

  • 1. In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.
    Oka D; Changkwanyeun R; Yamaguchi T; Nakajima C; Suzuki Y; Matsumoto M
    J Antimicrob Chemother; 2022 Nov; 77(12):3248-3255. PubMed ID: 36101508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
    Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y
    J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
    Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
    Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin as an anti-quinolone-resistance antibiotic.
    Morimoto Y; Baba T; Sasaki T; Hiramatsu K
    Int J Antimicrob Agents; 2015 Dec; 46(6):666-73. PubMed ID: 26526895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
    D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
    PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
    Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
    Huband MD; Bradford PA; Otterson LG; Basarab GS; Kutschke AC; Giacobbe RA; Patey SA; Alm RA; Johnstone MR; Potter ME; Miller PF; Mueller JP
    Antimicrob Agents Chemother; 2015 Jan; 59(1):467-74. PubMed ID: 25385112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
    Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
    Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
    Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
    J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Oka D; Yamaya N; Kuno T; Asakawa Y; Shiragiku T; Chen L; Xue J; Mamuti A; Ye F; Sun J; Ohguro K; Miyamoto H; Uematsu Y; Inagaki K; Cheng JF; Matsumoto M
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
    Hu XE; Kim NK; Gray JL; Almstead JI; Seibel WL; Ledoussal B
    J Med Chem; 2003 Aug; 46(17):3655-61. PubMed ID: 12904069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
    Fedorowicz J; Sączewski J; Konopacka A; Waleron K; Lejnowski D; Ciura K; Tomašič T; Skok Ž; Savijoki K; Morawska M; Gilbert-Girard S; Fallarero A
    Eur J Med Chem; 2019 Oct; 179():576-590. PubMed ID: 31279292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
    Alt S; Mitchenall LA; Maxwell A; Heide L
    J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
    Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives.
    Leyva-Ramos S; de Loera D; Cardoso-Ortiz J
    Chemotherapy; 2017; 62(3):194-198. PubMed ID: 28334702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.